Last reviewed · How we verify
D+Z
D+Z is a fixed-dose combination of daclatasvir and sofosbuvir that inhibits hepatitis C virus NS5A and NS5B proteins to block viral replication.
D+Z is a fixed-dose combination of daclatasvir and sofosbuvir that inhibits hepatitis C virus NS5A and NS5B proteins to block viral replication. Used for Chronic hepatitis C virus infection (genotype-independent).
At a glance
| Generic name | D+Z |
|---|---|
| Sponsor | Sequential Medicine Ltd |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Daclatasvir is an NS5A inhibitor that disrupts hepatitis C virus replication and assembly, while sofosbuvir is a nucleotide analog NS5B polymerase inhibitor that terminates viral RNA chain elongation. Together, they provide a direct-acting antiviral combination effective against multiple HCV genotypes without requiring ribavirin or interferon.
Approved indications
- Chronic hepatitis C virus infection (genotype-independent)
Common side effects
- Headache
- Fatigue
- Nausea
Key clinical trials
- Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (PHASE2)
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (PHASE2, PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma (PHASE3)
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PHASE3)
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (NA)
- Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D+Z CI brief — competitive landscape report
- D+Z updates RSS · CI watch RSS
- Sequential Medicine Ltd portfolio CI